Use of the FreeStyle Libre system and diabetes treatment progression in T2DM : Results from a retrospective cohort study using a Canadian private payer claims database
Main finding · Treatment progressionResult — go to the resultRelative risk 1.86 and 2.81Authors' conclusion
People with T2DM using FSL had a greater probability for treatment progression compared with BGM alone, irrespective of the starting therapy, which may suggest that FSL can be used to support escalation of diabetes therapy to improve therapeutic inertia in T2DM.
Study context
- Population
- People with T2D in a Canadian national private drug claims database (≈50% coverage of insured individuals), followed over 24 months
- Participants
- 373,871 people
- Exposure
- FreeStyle Libre flash glucose monitoring (FSL) vs blood glucose monitoring (BGM) alone
- Outcome
- Rate of diabetes treatment progression
- Follow-up
- 24-month study period
Methodological detailsprivate drug claims database, Andersen-Gill recurrent time-to-event model
- Private drug claims database
- Andersen-Gill recurrent time-to-event model
Main finding
Treatment progression
Relative risk
1.86 and 2.81
P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Further findings
Treatment progression by starting therapy or patient status
- Higher probability of progression with FSL independent of treatment at index date, patient status, and treatment-naïve vs established therapy
Ending vs starting therapy
- Much greater portion of FSL cohort ended on insulin after starting non-insulin treatment vs BGM cohort
Original publication
Use of the FreeStyle Libre system and diabetes treatment progression in T2DM : Results from a retrospective cohort study using a Canadian private payer claims database. Diabetes Obes Metab. Published 8 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →